Skip to main content
    I

    IDEXX Laboratories Inc (IDXX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $700.65
    -3.58 (-0.51%)

    Market Cap: $55.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    IDEXX Laboratories Inc (IDXX) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    IDEXX Laboratories (IDXX) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, IDEXX Laboratories reported EPS of $3.98, above the $3.71 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    98%(39/40)
    Avg Surprise
    +10.19%
    Streak
    17 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$3.38
    Range$3.19 - $3.57
    15 analysts
    Revenue Consensus
    $1.21B
    Range$1.16B - $1.25B
    13 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.96
    Range$3.88 - $4.03
    7 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$3.94+0.5%
    60d ago$3.96+0.1%
    30d ago$3.96+0.1%
    7d ago$3.96-0.1%
    Current$3.96
    Revenue Consensus
    $1.24B
    Range$1.23B - $1.27B
    5 analysts

    Next Report

    IDXX has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.7% above the $3.08 reported for the quarter ended Dec 31, 2025.

    IDXX Earnings Call

    The latest IDXX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IDXX beat 39 and missed 1. Revenue for the quarter ended Sep 30, 2026 was $1.21B, up 9.0% from $1.11B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.98$3.71$3.37 - $3.91+7.28%Beat+17.1%103 up, 7 downNov 2, 2026$1.21B
    Jun 30, 2026$4.27$3.95$3.81 - $4.03+8.10%Beat+17.6%123 up, 3 downAug 4, 2026$1.22B
    Mar 31, 2026$3.47$3.41$3.35 - $3.48+1.76%Beat+17.2%110 up, 1 downMay 5, 2026$1.14B
    Dec 31, 2025$3.08$2.94$2.87 - $3.00+4.76%Beat+17.6%101 up, 0 downFeb 2, 2026$1.09B
    Sep 30, 2025$3.40$3.15$2.99 - $3.18+7.94%Beat+21.4%111 up, 0 downNov 3, 2025$1.11B
    Jun 30, 2025$3.63$3.30$3.26 - $3.35+10.00%Beat+20.2%93 up, 0 downAug 4, 2025$1.11B
    Mar 31, 2025$2.96$2.84$2.77 - $2.95+4.23%Beat+5.3%91 up, 4 downMay 1, 2025$998.43M
    Dec 31, 2024$2.62$2.40$2.35 - $2.47+9.17%Beat+12.9%90 up, 0 downFeb 3, 2025$954.29M
    Sep 30, 2024$2.80$2.69$2.64 - $2.71+4.09%Beat+10.7%90 up, 0 downOct 31, 2024$975.54M
    Jun 30, 2024$3.02$2.87$2.84 - $2.97+5.23%Beat+13.1%91 up, 0 downAug 6, 2024$1.00B
    Mar 31, 2024$2.81$2.67$2.60 - $2.75+5.24%Beat+10.2%81 up, 0 downMay 1, 2024$964.10M
    Dec 31, 2023$2.32$2.12$2.08 - $2.19+9.43%Beat+13.2%84 up, 0 downFeb 5, 2024$901.60M
    Sep 30, 2023$2.53$2.37$2.28 - $2.43+6.75%Beat+17.7%80 up, 0 downNov 1, 2023$915.53M
    Jun 30, 2023$2.67$2.47$2.39 - $2.60+8.10%Beat+71.2%90 up, 0 downAug 1, 2023$943.63M
    Mar 31, 2023$2.55$2.43$2.31 - $2.56+4.94%Beat+12.3%91 up, 0 downMay 2, 2023$900.20M
    Dec 31, 2022$2.05$1.92$1.85 - $2.01+6.77%Beat+8.5%93 up, 0 downFeb 6, 2023$828.57M
    Sep 30, 2022$2.15$2.04$1.96 - $2.08+5.39%Beat+5.9%101 up, 2 downNov 1, 2022$841.66M
    Jun 30, 2022$1.56$1.63$1.49 - $2.35-4.29%Miss-33.3%101 up, 1 downAug 2, 2022$860.55M
    Mar 31, 2022$2.27$2.25$2.15 - $2.37+0.89%Beat-3.4%91 up, 1 downMay 4, 2022$836.55M
    Dec 31, 2021$1.89$1.72$1.65 - $2.01+9.88%Beat+7.4%80 up, 0 downFeb 2, 2022$801.09M
    Sep 30, 2021$2.03$1.91$1.66 - $2.07+6.28%Beat+20.1%8N/ANov 2, 2021$810.42M
    Jun 30, 2021$2.34$2.04$1.90 - $2.17+14.71%Beat+36.0%8N/AJul 30, 2021$826.14M
    Mar 31, 2021$2.35$1.72$1.60 - $1.80+36.63%Beat+82.2%8N/AMay 4, 2021$777.71M
    Dec 31, 2020$1.76$1.39$1.19 - $1.53+26.62%Beat+69.2%8N/AFeb 2, 2021$720.94M
    Sep 30, 2020$1.69$1.44$1.35 - $1.49+17.36%Beat+36.3%7N/AOct 29, 2020$721.79M
    Jun 30, 2020$1.72$1.17$0.89 - $1.40+47.01%Beat+20.3%7N/AJul 31, 2020$637.59M
    Mar 31, 2020$1.29$1.20$1.06 - $1.26+7.50%Beat+10.3%7N/AApr 30, 2020$626.34M
    Dec 31, 2019$1.04$0.90$0.87 - $0.93+15.56%Beat+6.1%7N/AJan 31, 2020N/A
    Sep 30, 2019$1.24$1.14$1.12 - $1.17+8.77%Beat+18.1%8N/AOct 31, 2019$605.30M
    Jun 30, 2019$1.43$1.37$1.35 - $1.39+4.38%Beat+16.3%7N/AAug 1, 2019$1.24B
    Mar 31, 2019$1.17$1.06$0.97 - $1.08+10.38%Beat+15.8%6N/AMay 1, 2019$576.06M
    Dec 31, 2018$0.98$0.91$0.89 - $0.92+7.69%Beat+27.3%6N/AFeb 1, 2019$549.39M
    Sep 30, 2018$1.05$0.97$0.93 - $0.99+8.25%Beat+32.9%7N/ANov 1, 2018$545.45M
    Jun 30, 2018$1.23$1.17$1.14 - $1.21+5.13%Beat+29.5%9N/AAug 1, 2018$580.75M
    Mar 31, 2018$1.01$0.92$0.90 - $0.99+9.78%Beat+31.2%10N/AMay 4, 2018$537.66M
    Dec 31, 2017$0.77$0.73$0.70 - $0.75+5.48%Beat+32.8%8N/AFeb 1, 2018$506.12M
    Sep 30, 2017$0.79$0.74$0.73 - $0.76+6.76%Beat+27.4%9N/AOct 31, 2017$491.98M
    Jun 30, 2017$0.95$0.85$0.82 - $0.88+11.76%Beat+28.4%9N/AAug 1, 2017$508.94M
    Mar 31, 2017$0.77$0.60N/A+28.33%Beat+51.0%N/AN/AApr 28, 2017$462.02M
    Dec 31, 2016$0.58$0.51N/A+13.73%Beat+20.8%N/AN/AFeb 2, 2017$443.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $13.07, up 16.2% from the year before. It was $2.45 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$13.07+16.2%
    Dec 31, 2024$11.25+11.7%
    Dec 31, 2023$10.07+25.4%
    Dec 31, 2022$8.03-6.7%
    Dec 31, 2021$8.61+33.3%
    Dec 31, 2020$6.46+32.4%
    Dec 31, 2019$4.88+14.3%
    Dec 31, 2018$4.27+30.2%
    Dec 31, 2017$3.28+33.9%
    Dec 31, 2016$2.45N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,100 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,06910
    2026Q2Jun 30, 20268,18510
    2026Q1Mar 31, 20268,35511
    2025Q4Dec 31, 20258,80710
    2025Q3Sep 30, 20256,64611
    2025Q2Jun 30, 20257,82411
    2025Q1Mar 31, 20258,27011
    2024Q4Dec 31, 20247,35810

    2026Q3 Earnings Call

    Opening remarks

    Andrew Emerson CFO Good morning. I am pleased to take you through our third quarter results and provide an updated outlook for our full-year 2026 financial expectations. During the third quarter, IDEXX delivered outstanding financial results, driven by strong global execution, the expanding impact of IDEXX Innovations, and continued progress in increasing the medically relevant use of diagnostics across our companion animal business. We also advanced our software, data, and AI capabilities through the acquisition of ezyVet. Revenue increased 10% organically, supported by 11% organic growth in CAG Diagnostics recurring revenues, reflecting nearly 14% gains in international regions and nearly 10% growth in the U.S. We saw strong demand for diagnostic solutions, including IDEXX Innovations, as demonstrated by premium instrument placements of nearly 5.8 thousand units, with over 1.9 thousand IDEXX InVue Dx analyzers. Operating performance was excellent, with comparable operating margin gains of approximately 60 basis points year over year, led by improvement in gross margin while making ongoing investments in the business, including costs related to the ezyVet acquisition. Strong operating profit gains enabled $4.10 per share in the quarter, an increase of 18% as reported and 22% on a comparable basis. Strong third-quarter performance supports an increase to our full-year revenue outlook. We are raising our full-year revenue range to $4.741 billion to $4.767 billion, a $32 million increase at the midpoint, reflecting strong third-quarter performance and approximately $5 million of revenue from ezyVet. Our updated full-year overall organic revenue growth outlook is 9.3% to 10%, with organic CAG Diagnostics recurring revenue growth of 10.3% to 11%. These ranges represent an increase of approximately 60 basis points at the midpoint, along with tightening the low end of the range as we enter the final quarter of the year. We also increased our full-year EPS outlook to $14.96 to $15.16 per share, an $0.25-per-share increase at the midpoint, reflecting 15% to 16% comparable EPS growth while observing near-term dilution related to the ezyVet acquisition. We will provide further details on our updated 2026 financial expectations later in my comments. Let's begin with a review of our third-quarter results. Third-quarter organic revenue growth of 10% was driven by 10% CAG revenue gains, 8% growth in our water business, and 3% growth in LPD. Strong CAG results were driven by CAG Diagnostics recurring revenue growth of 11% organically, which was volume-led, reflecting strong execution and contributions from innovations, and included approximately 4% global net price improvement. Demand for IDEXX diagnostic solutions remains high, and we have realized benefits from net new customer gains, expansion of our premium instrument installed base, and increased utilization of IDEXX Innovations. U.S.

    Frequently Asked Questions About IDXX

    When is IDEXX Laboratories's next earnings date?

    IDEXX Laboratories's next earnings report is expected for Feb 1, 2027.

    Did IDXX beat earnings estimates last quarter?

    Yes. IDEXX Laboratories reported EPS of $3.98 for the quarter ended Sep 30, 2026, above the $3.71 estimate, a 7.28% surprise.

    What EPS do analysts expect from IDXX next quarter?

    The consensus EPS estimate for IDEXX Laboratories for the quarter ending Dec 31, 2026 is $3.38 from 15 analysts, with estimates from $3.19 to $3.57.

    How often does IDXX beat earnings estimates?

    IDEXX Laboratories beat the EPS estimate in each of the last 17 quarters, with an average surprise of +6.42%.